BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zonisamide (Zonisade) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zonisamide (Zonisade)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06534502-9020@assetmemo.bio
DTSTAMP:20261121T005444Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Zonisamide (Zonisade): Phase 4 readout est. (NCT06534502)
DESCRIPTION:Zonisamide (Zonisade)\, phase 4\, Epilepsy.\nStudy: Study of th
 e Pharmacokinetics\, Safety\, and Tolerability of ZONISADE in Children 1 M
 onth to 17 Years of Age With Partial-onset Seizures\nEstimated primary com
 pletion: September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/zonisamide-zonisade#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06534502
URL:https://assetmemo.bio/drug/zonisamide-zonisade#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
